Free Trial

Bausch Health Companies (BHC) Financials

Bausch Health Companies logo
$5.30 +0.14 (+2.61%)
As of 11:12 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Bausch Health Companies

Annual Income Statements for Bausch Health Companies

This table shows Bausch Health Companies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
881 -292 -2,409 2,404 -4,148 -1,788 -6,316 -948 -225 -592 -46
Consolidated Net Income / (Loss)
880 -288 -2,408 2,404 -4,144 -1,783 -559 -937 -212 -611 -72
Net Income / (Loss) Continuing Operations
880 -288 -2,408 2,404 -4,144 -1,783 -6,315 -937 -212 -611 -72
Total Pre-Tax Income
1,054 -155 -2,435 -1,741 -4,154 -1,837 -6,690 -1,024 -129 -390 167
Total Operating Income
2,001 1,527 -566 102 -2,384 -203 676 450 454 963 1,546
Total Gross Profit
6,028 7,915 7,063 6,176 6,029 6,251 0.00 6,040 5,760 6,198 6,843
Total Revenue
8,206 10,447 9,674 8,724 8,380 8,601 0.00 8,434 8,124 8,757 9,625
Operating Revenue
8,206 10,447 9,674 8,724 8,380 8,601 - 8,434 8,124 8,757 9,625
Total Cost of Revenue
2,178 2,532 2,611 2,548 2,351 2,350 0.00 2,394 2,364 2,559 2,782
Operating Cost of Revenue
2,178 2,532 2,611 2,548 2,351 2,350 0.00 2,394 2,364 2,559 2,782
Total Operating Expenses
4,027 6,388 7,629 6,074 8,413 6,454 5,080 5,590 5,306 5,235 5,297
Selling, General & Admin Expense
2,026 2,700 2,810 2,582 2,473 2,554 2,367 2,624 2,625 2,917 3,296
Research & Development Expense
266 440 455 361 413 471 452 465 529 604 616
Amortization Expense
1,427 2,257 2,673 2,690 2,644 1,897 1,645 1,375 1,215 1,077 1,077
Other Operating Expenses / (Income)
-219 325 60 -637 -29 1,426 502 373 35 28 247
Impairment Charge
145 304 1,499 1,026 2,890 75 114 703 839 547 29
Restructuring Charge
382 362 132 52 22 31 - 50 63 62 32
Total Other Income / (Expense), net
-947 -1,682 -1,869 -1,843 -1,770 -1,634 -1,610 -1,474 -583 -1,353 -1,379
Interest Expense
1,101 1,583 1,836 1,962 1,804 1,654 1,593 1,488 589 1,327 1,365
Interest & Investment Income
298 4.00 8.00 12 11 12 13 7.00 14 26 33
Other Income / (Expense), net
-144 -103 -41 107 23 8.00 -30 7.00 -8.00 -52 -47
Income Tax Expense
174 133 -27 -4,145 -10 -54 -375 -87 83 221 239
Net Income / (Loss) Attributable to Noncontrolling Interest
-1.00 4.00 1.00 0.00 4.00 5.00 1.00 11 13 -19 -26
Basic Earnings per Share
$2.63 ($0.85) ($6.94) $6.86 ($11.81) ($5.08) ($1.58) ($2.64) ($0.62) ($1.62) ($0.13)
Weighted Average Basic Shares Outstanding
335.40M 342.70M 347.30M 350.20M 351.30M 352.10M 355M 358.90M 362M 364.90M 368M
Diluted Earnings per Share
$2.58 ($0.85) ($6.94) $6.83 ($11.81) ($5.08) ($1.58) ($2.64) ($0.62) ($1.62) ($0.13)
Weighted Average Diluted Shares Outstanding
341.50M 342.70M 347.30M 351.80M 351.30M 352.10M 355M 358.90M 362M 364.90M 368M
Weighted Average Basic & Diluted Shares Outstanding
323.80M 343.50M 347.10M 350.40M 351.30M 352.10M 355M 359.65M 362.04M 365.41M 367.93M

Quarterly Income Statements for Bausch Health Companies

This table shows Bausch Health Companies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
399 -410 -201 26 -378 -39 -64 10 -85 93
Consolidated Net Income / (Loss)
403 -410 -209 27 -382 -47 -77 -1.00 -92 98
Net Income / (Loss) Continuing Operations
403 -410 -209 27 -382 -47 -77 -1.00 -92 98
Total Pre-Tax Income
439 -357 -136 79 -326 -7.00 -69 48 -21 209
Total Operating Income
244 -236 175 412 14 362 281 389 318 558
Total Gross Profit
1,462 1,541 1,362 1,518 1,615 1,703 1,513 1,684 1,814 1,832
Total Revenue
2,046 2,193 1,944 2,167 2,238 2,408 2,153 2,403 2,510 2,559
Operating Revenue
2,046 2,193 1,944 2,167 2,238 2,408 2,153 2,403 2,510 2,559
Total Cost of Revenue
584 652 582 649 623 705 640 719 696 727
Operating Cost of Revenue
584 652 582 649 623 705 640 719 696 727
Total Operating Expenses
1,218 1,777 1,187 1,106 1,601 1,341 1,232 1,295 1,496 1,274
Selling, General & Admin Expense
661 666 725 711 715 766 794 832 850 820
Research & Development Expense
133 142 143 156 153 152 151 156 146 163
Amortization Expense
290 313 273 269 253 282 274 270 274 259
Other Operating Expenses / (Income)
4.00 29 23 -83 60 28 0.00 20 225 2.00
Impairment Charge
120 622 13 37 406 91 1.00 5.00 0.00 23
Restructuring Charge
10 5.00 10 16 14 22 12 12 1.00 7.00
Total Other Income / (Expense), net
195 -121 -311 -333 -340 -369 -350 -341 -339 -349
Interest Expense
-185 115 307 319 339 362 344 338 346 337
Interest & Investment Income
3.00 6.00 6.00 7.00 6.00 7.00 9.00 8.00 7.00 9.00
Other Income / (Expense), net
7.00 -12 -10 -21 -7.00 -14 -15 -11 0.00 -21
Income Tax Expense
36 53 73 52 56 40 8.00 49 71 111
Net Income / (Loss) Attributable to Noncontrolling Interest
4.00 - -8.00 1.00 -4.00 -8.00 -13 -11 -7.00 5.00
Basic Earnings per Share
$1.10 ($1.13) ($0.55) $0.07 ($1.03) ($0.11) ($0.17) $0.03 ($0.23) $0.24
Weighted Average Basic Shares Outstanding
362.50M 362M 363.30M 364.80M 365.40M 364.90M 366.80M 367.90M 368.40M 368M
Diluted Earnings per Share
$1.10 ($1.13) ($0.55) $0.07 ($1.03) ($0.11) ($0.17) $0.03 ($0.23) $0.24
Weighted Average Diluted Shares Outstanding
363.40M 362M 363.30M 367.10M 365.40M 364.90M 366.80M 370.20M 368.40M 368M
Weighted Average Basic & Diluted Shares Outstanding
361.87M 362.04M 363.72M 364.33M 365.20M 365.41M 366.80M 367.10M 367.80M 367.93M

Annual Cash Flow Statements for Bausch Health Companies

This table details how cash moves in and out of Bausch Health Companies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
-277 274 -55 255 -48 2,521 -1,428 303 -1,528 371 239
Net Cash From Operating Activities
2,312 2,257 2,087 2,290 1,501 1,501 1,111 1,426 -728 1,032 1,597
Net Cash From Continuing Operating Activities
2,312 2,257 2,087 2,290 1,501 1,501 1,111 1,426 -728 1,032 1,597
Net Income / (Loss) Continuing Operations
880 -288 -2,408 2,404 -4,144 -1,783 -559 -937 -212 -611 -72
Consolidated Net Income / (Loss)
880 -288 -2,408 2,404 -4,144 -1,783 -559 -937 -212 -611 -72
Depreciation Expense
1,614 2,467 2,866 2,858 2,819 2,075 1,825 1,552 1,394 1,264 1,267
Amortization Expense
70 145 118 151 79 63 61 55 99 88 137
Non-Cash Adjustments To Reconcile Net Income
312 761 1,857 419 2,873 1,694 625 1,109 -1,437 822 192
Changes in Operating Assets and Liabilities, net
-564 -828 -346 -3,542 -126 -548 -841 -353 -572 -531 73
Net Cash From Investing Activities
-100 -15,577 -125 2,887 -196 -419 -261 409 -303 -2,145 -454
Net Cash From Continuing Investing Activities
-100 -15,577 -125 2,887 -196 -419 -261 409 -303 -2,145 -454
Purchase of Property, Plant & Equipment
-292 -235 -235 -171 -157 -270 -302 -269 -218 -215 -337
Acquisitions
-1,357 -15,526 -86 -165 -78 -188 -7.00 -14 -50 -57 -3.00
Purchase of Investments
-72 -49 -1.00 -7.00 -7.00 -16 -4.00 -19 -62 -1,917 -148
Divestitures
76 0.00 199 3,253 39 45 21 669 5.00 5.00 7.00
Sale and/or Maturity of Investments
53 251 17 2.00 7.00 10 8.00 15 22 26 14
Other Investing Activities, net
0.00 -31 -19 -25 0.00 0.00 23 27 0.00 13 13
Net Cash From Financing Activities
-2,460 13,624 -1,963 -4,963 -1,353 1,443 -2,294 -1,513 -474 1,475 -868
Net Cash From Continuing Financing Activities
-2,460 13,624 -1,963 -4,963 -1,353 1,443 -2,294 -1,513 -474 1,475 -868
Repayment of Debt
-3,968 -5,289 -2,545 -14,339 -10,232 -4,454 -5,684 -3,478 -7,928 -1,757 -1,476
Issuance of Debt
1,649 17,825 1,223 9,425 8,944 5,972 3,455 2,100 6,836 3,291 661
Other Financing Activities, net
-133 -264 -641 -49 -65 -75 -65 -135 618 -59 -53
Effect of Exchange Rate Changes
-29 -30 -54 41 - -4.00 16 -19 -23 9.00 -36

Quarterly Cash Flow Statements for Bausch Health Companies

This table details how cash moves in and out of Bausch Health Companies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-1,382 94 -60 57 192 182 -207 -132 127 451
Net Cash From Operating Activities
-1,263 475 154 206 282 390 211 380 405 601
Net Cash From Continuing Operating Activities
-1,263 475 154 206 282 390 211 380 405 601
Net Income / (Loss) Continuing Operations
403 -410 -209 27 -382 -47 -77 -1.00 -92 98
Consolidated Net Income / (Loss)
403 -410 -209 27 -382 -47 -77 -1.00 -92 98
Depreciation Expense
335 360 319 315 301 329 320 318 322 307
Amortization Expense
22 13 11 12 28 37 34 34 34 35
Non-Cash Adjustments To Reconcile Net Income
-1,658 515 94 85 486 157 26 41 18 107
Changes in Operating Assets and Liabilities, net
-365 -3.00 -61 -233 -151 -86 -92 -12 123 54
Net Cash From Investing Activities
-53 -136 -78 -30 -1,889 -148 -73 -79 -102 -200
Net Cash From Continuing Investing Activities
-53 -136 -78 -30 -1,889 -148 -73 -79 -102 -200
Purchase of Property, Plant & Equipment
-54 -66 -47 -28 -42 -98 -82 -78 -71 -106
Acquisitions
-5.00 -30 -4.00 -3.00 -4.00 -46 -1.00 -1.00 - -1.00
Purchase of Investments
-1.00 -47 -44 2.00 -1,858 -17 -3.00 -2.00 -47 -96
Sale and/or Maturity of Investments
7.00 2.00 11 -2.00 4.00 13 6.00 1.00 4.00 3.00
Net Cash From Financing Activities
-36 -276 -142 -120 1,816 -79 -340 -424 -189 85
Net Cash From Continuing Financing Activities
-36 -276 -142 -120 1,816 -79 -340 -424 -189 85
Repayment of Debt
-190 -623 -278 -413 -860 -206 -394 -495 -176 -411
Issuance of Debt
161 355 155 300 2,690 146 75 80 - 506
Other Financing Activities, net
-7.00 -8.00 -19 -7.00 -14 -19 -21 -9.00 -13 -10
Effect of Exchange Rate Changes
-30 31 6.00 1.00 -17 19 -5.00 -9.00 13 -35

Annual Balance Sheets for Bausch Health Companies

This table presents Bausch Health Companies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
26,305 48,965 43,529 37,497 32,492 33,863 31,199 29,202 25,686 27,350 26,523
Total Current Assets
4,132 5,507 5,077 4,746 4,211 6,969 5,342 5,607 4,247 5,596 5,774
Cash & Equivalents
323 597 542 720 721 3,243 605 582 564 947 1,181
Restricted Cash
- - 0.00 77 2.00 1.00 1,211 1,537 - 15 20
Accounts Receivable
2,076 2,687 2,517 2,130 1,865 1,839 1,577 1,775 1,790 1,998 2,140
Inventories, net
889 1,257 1,061 1,048 934 1,107 1,094 993 1,090 1,544 1,595
Prepaid Expenses
651 963 696 771 689 779 855 720 776 1,092 838
Plant, Property, & Equipment, net
1,312 1,442 1,312 1,403 1,353 1,466 1,567 1,598 1,600 1,707 1,780
Total Noncurrent Assets
20,861 42,016 37,140 31,348 26,928 25,428 24,290 21,997 19,839 20,047 18,969
Goodwill
9,361 18,553 15,794 15,593 13,142 13,126 13,044 12,457 11,547 11,183 11,087
Intangible Assets
11,278 23,083 18,884 15,211 12,001 10,201 8,445 6,948 5,800 6,456 5,551
Noncurrent Deferred & Refundable Income Taxes
54 156 146 433 1,676 1,690 2,137 2,252 2,166 2,101 1,968
Other Noncurrent Operating Assets
167 224 184 111 109 411 664 340 326 307 363
Total Liabilities & Shareholders' Equity
26,305 48,965 43,529 37,497 32,492 33,863 31,199 29,202 25,686 27,350 26,523
Total Liabilities
20,903 42,936 40,271 31,553 29,677 32,727 30,594 29,236 25,426 27,432 26,845
Total Current Liabilities
2,708 5,313 3,609 4,268 3,836 6,248 4,913 5,198 3,941 4,302 6,752
Short-Term Debt
143 1,020 1.00 209 228 1,234 - 0.00 432 450 2,674
Accounts Payable
398 434 324 365 411 503 337 407 521 719 656
Accrued Expenses
2,157 3,859 3,227 3,694 3,197 4,511 4,576 4,791 2,988 3,133 3,422
Total Noncurrent Liabilities
18,195 37,623 36,662 27,285 25,841 26,479 25,681 24,038 21,485 23,130 20,093
Long-Term Debt
15,228 30,265 29,845 25,235 24,077 24,661 23,925 22,654 20,334 21,938 18,942
Noncurrent Deferred & Payable Income Tax Liabilities
2,324 6,023 5,434 1,180 885 705 528 529 202 163 128
Other Noncurrent Operating Liabilities
403 1,144 1,326 870 879 1,113 1,228 855 949 1,029 1,023
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
5,402 6,029 3,258 5,944 2,815 1,136 605 -34 260 -82 -322
Total Preferred & Common Equity
5,279 5,910 3,152 5,849 2,733 1,063 535 -106 -692 -1,022 -1,279
Total Common Equity
5,279 5,910 3,152 5,849 2,733 1,063 535 -106 -692 -1,022 -1,279
Common Stock
8,593 10,202 10,389 10,470 10,534 10,601 10,681 10,779 10,550 10,637 10,724
Retained Earnings
-2,398 -2,750 -5,129 -2,725 -5,664 -7,452 -8,013 -8,961 -9,186 -9,778 -9,824
Accumulated Other Comprehensive Income / (Loss)
-916 -1,542 -2,108 -1,896 -2,137 -2,086 -2,133 -1,924 -2,056 -1,881 -2,179
Noncontrolling Interest
122 119 106 95 82 73 70 72 952 940 957

Quarterly Balance Sheets for Bausch Health Companies

This table presents Bausch Health Companies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
26,298 25,445 25,503 27,064 26,913 26,495 26,540
Total Current Assets
4,010 4,237 4,461 5,048 5,396 5,211 5,351
Cash & Equivalents
486 518 579 760 733 595 719
Restricted Cash
11 13 9.00 20 22 28 31
Accounts Receivable
1,739 1,688 1,743 1,948 2,048 2,102 2,094
Inventories, net
1,056 1,222 1,240 1,272 1,636 1,612 1,655
Prepaid Expenses
718 796 890 1,048 957 874 852
Plant, Property, & Equipment, net
1,507 1,596 1,599 1,584 1,713 1,738 1,789
Total Noncurrent Assets
20,781 19,612 19,443 20,432 19,804 19,546 19,400
Goodwill
12,044 11,579 11,628 11,187 11,160 11,127 11,171
Intangible Assets
6,024 5,552 5,299 6,728 6,183 5,903 5,652
Noncurrent Deferred & Refundable Income Taxes
2,372 2,163 2,191 2,189 2,149 2,187 2,188
Other Noncurrent Operating Assets
341 318 325 328 312 329 389
Total Liabilities & Shareholders' Equity
26,298 25,445 25,503 27,064 26,913 26,495 26,540
Total Liabilities
25,865 25,300 25,232 27,299 27,087 26,722 26,782
Total Current Liabilities
3,831 3,923 3,967 4,224 4,405 4,369 4,506
Short-Term Debt
411 446 444 536 538 452 453
Accounts Payable
486 561 515 569 642 579 667
Accrued Expenses
2,934 2,916 3,008 3,119 3,225 3,338 3,386
Total Noncurrent Liabilities
22,034 21,377 21,265 23,075 22,682 22,353 22,028
Long-Term Debt
20,804 20,207 20,108 21,894 21,536 21,208 21,054
Noncurrent Deferred & Payable Income Tax Liabilities
422 205 215 213 170 170 169
Other Noncurrent Operating Liabilities
808 965 942 968 976 975 805
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
433 145 271 -235 -174 -227 -242
Total Preferred & Common Equity
-525 -800 -663 -1,180 -1,115 -1,175 -1,174
Total Common Equity
-525 -800 -663 -1,180 -1,115 -1,175 -1,174
Common Stock
10,516 10,576 10,600 10,610 10,644 10,664 10,690
Retained Earnings
-8,776 -9,387 -9,361 -9,739 -9,842 -9,832 -9,917
Accumulated Other Comprehensive Income / (Loss)
-2,265 -1,989 -1,902 -2,051 -1,917 -2,007 -1,947
Noncontrolling Interest
958 945 934 945 941 948 932

Annual Metrics and Ratios for Bausch Health Companies

This table displays calculated financial ratios and metrics derived from Bausch Health Companies' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
42.23% 27.31% -7.40% -9.82% -3.94% 2.64% -100.00% 0.00% -3.68% 7.79% 9.91%
EBITDA Growth
109.97% 13.98% -41.11% 35.38% -83.31% 261.83% 30.31% -18.48% -6.06% 16.71% 28.28%
EBIT Growth
543.30% -23.32% -142.63% 134.43% -1,229.67% 91.74% 431.28% -29.26% -2.41% 104.26% 64.54%
NOPAT Growth
682.82% -36.02% -137.07% 118.02% -2,437.25% 91.48% 433.00% -33.43% 0.89% 112.11% -198.88%
Net Income Growth
201.90% -132.73% -736.11% 199.83% -272.38% 56.97% 68.65% -67.62% 77.37% -188.21% 88.22%
EPS Growth
195.56% -132.95% -716.47% 198.42% -272.91% 56.99% 68.90% -67.09% 76.52% -161.29% 91.98%
Operating Cash Flow Growth
121.88% -2.38% -7.53% 9.73% -34.45% 0.00% -25.98% 28.35% -151.05% 241.76% 54.75%
Free Cash Flow Firm Growth
138.80% -557.67% 139.71% -103.92% 1,167.29% -2.27% -37.35% 63.50% -85.89% -158.27% 381.13%
Invested Capital Growth
-7.46% 79.53% -17.52% 1.02% -13.71% -9.89% -4.51% -9.74% -0.19% 4.31% -5.86%
Revenue Q/Q Growth
1.97% 5.40% -3.54% -2.68% -0.50% 1.21% -100.00% 1,889.15% 2,746.25% 2.52% 1.59%
EBITDA Q/Q Growth
7.76% -0.47% -1.74% -7.82% 4.88% -37.52% 66.25% 17.27% -24.05% 35.19% 6.03%
EBIT Q/Q Growth
19.79% -20.23% -10.61% -66.07% 12.33% -121.31% 252.00% 437.65% -57.81% 189.21% 14.43%
NOPAT Q/Q Growth
-12.96% -39.86% -3.04% -82.23% 12.71% -122.61% 271.14% 476.92% -57.05% 163.84% -170.53%
Net Income Q/Q Growth
74.92% -147.96% -5.49% 74.20% -25.96% -193.26% 70.95% 19.29% -178.52% 37.27% 66.82%
EPS Q/Q Growth
85.61% -148.85% -5.63% 76.03% -25.77% -191.95% 71.01% 19.51% -186.11% 38.64% 72.92%
Operating Cash Flow Q/Q Growth
31.45% -9.46% -3.92% 2.97% -14.72% -5.36% 16.82% -20.60% 38.25% -7.61% 15.22%
Free Cash Flow Firm Q/Q Growth
9.01% -12.89% 306.88% -105.82% 69.33% 6.16% -23.17% -7.93% 487.41% -2,345.88% -63.40%
Invested Capital Q/Q Growth
-1.16% 2.19% -11.09% 0.63% -2.22% -5.98% -1.29% 0.90% -3.26% -0.33% -3.23%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
73.46% 75.76% 73.01% 70.79% 71.95% 72.68% 0.00% 71.61% 70.90% 70.78% 71.10%
EBITDA Margin
43.15% 38.63% 24.57% 36.89% 6.41% 22.59% 0.00% 24.47% 23.87% 25.84% 30.16%
Operating Margin
24.38% 14.62% -5.85% 1.17% -28.45% -2.36% 0.00% 5.34% 5.59% 11.00% 16.06%
EBIT Margin
22.63% 13.63% -6.27% 2.40% -28.17% -2.27% 0.00% 5.42% 5.49% 10.40% 15.57%
Profit (Net Income) Margin
10.72% -2.76% -24.89% 27.56% -49.45% -20.73% 0.00% -11.11% -2.61% -6.98% -0.75%
Tax Burden Percent
83.49% 185.81% 98.89% -138.08% 99.76% 97.06% 8.36% 91.50% 164.34% 156.67% -43.11%
Interest Burden Percent
56.76% -10.88% 401.15% -833.01% 175.94% 942.05% -1,035.60% -224.07% -28.92% -42.81% 11.14%
Effective Tax Rate
16.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 143.11%
Return on Invested Capital (ROIC)
7.85% 3.74% -1.18% 0.23% -5.86% -0.57% 0.00% 1.46% 1.55% 3.22% -3.22%
ROIC Less NNEP Spread (ROIC-NNEP)
2.90% -2.19% -8.15% 9.26% -16.12% -7.66% 0.00% -4.41% -1.05% -2.95% -0.38%
Return on Net Nonoperating Assets (RNNOA)
8.70% -8.78% -50.67% 52.01% -88.77% -89.69% 0.00% -329.65% -189.16% -689.74% 38.86%
Return on Equity (ROE)
16.55% -5.04% -51.86% 52.25% -94.62% -90.26% -64.22% -328.20% -187.61% -686.52% 35.64%
Cash Return on Invested Capital (CROIC)
15.61% -53.16% 18.02% -0.78% 8.86% 9.84% 6.65% 11.70% 1.74% -0.99% 2.82%
Operating Return on Assets (OROA)
6.84% 3.78% -1.31% 0.52% -6.75% -0.59% 0.00% 1.51% 1.63% 3.44% 5.56%
Return on Assets (ROA)
3.24% -0.77% -5.21% 5.93% -11.84% -5.37% 0.00% -3.10% -0.77% -2.30% -0.27%
Return on Common Equity (ROCE)
16.18% -4.93% -50.60% 51.11% -92.71% -86.71% -58.94% -246.58% 662.45% 6,610.62% 203.01%
Return on Equity Simple (ROE_SIMPLE)
16.67% -4.87% -76.40% 41.10% -151.63% -167.73% -104.49% 883.96% 30.64% 59.78% 5.63%
Net Operating Profit after Tax (NOPAT)
1,671 1,069 -396 71 -1,669 -142 473 315 318 674 -667
NOPAT Margin
20.36% 10.23% -4.10% 0.82% -19.91% -1.65% 0.00% 3.73% 3.91% 7.70% -6.93%
Net Nonoperating Expense Percent (NNEP)
4.96% 5.93% 6.97% -9.03% 10.26% 7.10% 4.61% 5.87% 2.60% 6.17% -2.84%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 1.51% 3.02% -3.13%
Cost of Revenue to Revenue
26.54% 24.24% 26.99% 29.21% 28.05% 27.32% 0.00% 28.39% 29.10% 29.22% 28.90%
SG&A Expenses to Revenue
24.69% 25.84% 29.05% 29.60% 29.51% 29.69% 0.00% 31.11% 32.31% 33.31% 34.24%
R&D to Revenue
3.24% 4.21% 4.70% 4.14% 4.93% 5.48% 0.00% 5.51% 6.51% 6.90% 6.40%
Operating Expenses to Revenue
49.07% 61.15% 78.86% 69.62% 100.39% 75.04% 0.00% 66.28% 65.31% 59.78% 55.03%
Earnings before Interest and Taxes (EBIT)
1,857 1,424 -607 209 -2,361 -195 646 457 446 911 1,499
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,541 4,036 2,377 3,218 537 1,943 2,532 2,064 1,939 2,263 2,903
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
9.10 5.90 1.60 1.24 2.36 9.92 13.81 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
5.85 3.34 0.52 0.83 0.77 1.23 0.00 1.18 0.28 0.33 0.31
Price to Earnings (P/E)
54.53 0.00 0.00 3.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
1.83% 0.00% 0.00% 33.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
3.09 1.79 1.14 1.05 1.14 1.40 1.30 1.49 1.14 1.19 1.21
Enterprise Value to Revenue (EV/Rev)
7.70 6.29 3.56 3.67 3.59 3.87 0.00 3.62 2.88 2.89 2.53
Enterprise Value to EBITDA (EV/EBITDA)
17.85 16.27 14.50 9.94 56.10 17.12 11.68 14.79 12.08 11.18 8.38
Enterprise Value to EBIT (EV/EBIT)
34.04 46.13 0.00 153.04 0.00 0.00 45.77 66.80 52.53 27.77 16.24
Enterprise Value to NOPAT (EV/NOPAT)
37.83 61.45 0.00 447.98 0.00 0.00 62.48 96.91 73.71 37.52 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
27.34 29.10 16.51 13.97 20.07 22.16 26.61 21.41 0.00 24.51 15.24
Enterprise Value to Free Cash Flow (EV/FCFF)
19.04 0.00 5.71 0.00 11.93 13.48 19.12 12.08 65.66 0.00 41.64
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
2.85 5.19 9.16 4.28 8.63 22.79 39.55 -666.29 79.87 -273.02 -67.13
Long-Term Debt to Equity
2.82 5.02 9.16 4.25 8.55 21.71 39.55 -666.29 78.21 -267.54 -58.83
Financial Leverage
3.00 4.00 6.21 5.62 5.51 11.70 25.71 74.68 180.25 233.87 -103.57
Leverage Ratio
5.10 6.58 9.96 8.81 7.99 16.79 37.37 105.78 242.87 297.96 -133.35
Compound Leverage Factor
2.90 -0.72 39.95 -73.35 14.06 158.21 -387.01 -237.02 -70.25 -127.55 -14.86
Debt to Total Capital
74.00% 83.84% 90.16% 81.06% 89.62% 95.80% 97.53% 100.15% 98.76% 100.37% 101.51%
Short-Term Debt to Total Capital
0.69% 2.73% 0.00% 0.67% 0.84% 4.57% 0.00% 0.00% 2.05% 2.02% 12.56%
Long-Term Debt to Total Capital
73.31% 81.11% 90.16% 80.40% 88.78% 91.23% 97.53% 100.15% 96.71% 98.35% 88.95%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.59% 0.32% 0.32% 0.30% 0.30% 0.27% 0.29% 0.32% 4.53% 4.21% 4.49%
Common Equity to Total Capital
25.42% 15.84% 9.52% 18.63% 10.08% 3.93% 2.18% -0.47% -3.29% -4.58% -6.01%
Debt to EBITDA
4.34 7.75 12.56 7.91 45.26 13.33 9.45 10.98 10.71 9.89 7.45
Net Debt to EBITDA
4.25 7.60 12.33 7.66 43.91 11.66 8.73 9.95 10.42 9.47 7.03
Long-Term Debt to EBITDA
4.30 7.50 12.56 7.84 44.84 12.69 9.45 10.98 10.49 9.69 6.53
Debt to NOPAT
9.20 29.27 -75.33 356.36 -14.56 -182.23 50.56 71.92 65.34 33.21 -32.43
Net Debt to NOPAT
9.01 28.71 -73.96 345.20 -14.13 -159.40 46.72 65.19 63.57 31.78 -30.63
Long-Term Debt to NOPAT
9.11 28.31 -75.33 353.43 -14.43 -173.55 50.56 71.92 63.98 32.54 -28.42
Altman Z-Score
1.86 0.72 0.13 0.30 -0.08 0.15 -0.13 0.13 -0.06 0.05 0.05
Noncontrolling Interest Sharing Ratio
2.23% 2.11% 2.42% 2.18% 2.02% 3.92% 8.21% 24.87% 453.10% 1,062.92% -469.55%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.53 1.04 1.41 1.11 1.10 1.12 1.09 1.08 1.08 1.30 0.86
Quick Ratio
0.89 0.62 0.85 0.67 0.67 0.81 0.44 0.45 0.60 0.68 0.49
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
3,320 -15,195 6,035 -237 2,525 2,468 1,546 2,528 357 -208 584
Operating Cash Flow to CapEx
0.00% 1,016.67% 888.09% 1,339.18% 956.05% 555.93% 367.88% 530.11% -333.95% 480.00% 473.89%
Free Cash Flow to Firm to Interest Expense
3.02 -9.60 3.29 -0.12 1.40 1.49 0.97 1.70 0.61 -0.16 0.43
Operating Cash Flow to Interest Expense
2.10 1.43 1.14 1.17 0.83 0.91 0.70 0.96 -1.24 0.78 1.17
Operating Cash Flow Less CapEx to Interest Expense
3.19 1.29 1.01 1.08 0.75 0.74 0.51 0.78 -1.61 0.62 0.92
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.30 0.28 0.21 0.22 0.24 0.26 0.00 0.28 0.30 0.33 0.36
Accounts Receivable Turnover
4.37 4.39 3.72 3.75 4.20 4.64 0.00 5.03 4.56 4.62 4.65
Inventory Turnover
2.46 2.36 2.25 2.42 2.37 2.30 0.00 2.29 2.27 1.94 1.77
Fixed Asset Turnover
6.44 7.59 7.03 6.43 6.08 6.10 0.00 5.33 5.08 5.30 5.52
Accounts Payable Turnover
6.01 6.09 6.89 7.40 6.06 5.14 0.00 6.44 5.09 4.13 4.05
Days Sales Outstanding (DSO)
83.45 83.20 98.17 97.21 87.00 78.59 0.00 72.53 80.09 78.94 78.46
Days Inventory Outstanding (DIO)
148.50 154.69 162.02 151.06 153.86 158.50 0.00 159.10 160.81 187.85 205.92
Days Payable Outstanding (DPO)
60.75 59.97 52.98 49.35 60.24 70.98 0.00 56.72 71.64 88.43 90.20
Cash Conversion Cycle (CCC)
171.20 177.93 207.21 198.92 180.62 166.12 0.00 174.91 169.25 178.36 194.18
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
20,450 36,714 30,283 30,591 26,397 23,787 22,714 20,501 20,462 21,344 20,093
Invested Capital Turnover
0.39 0.37 0.29 0.29 0.29 0.34 0.00 0.39 0.40 0.42 0.46
Increase / (Decrease) in Invested Capital
-1,650 16,264 -6,431 308 -4,194 -2,610 -1,073 -2,213 -39 882 -1,251
Enterprise Value (EV)
63,209 65,683 34,458 31,986 30,125 33,269 29,566 30,528 23,427 25,295 24,336
Market Capitalization
48,038 34,876 5,048 7,244 6,461 10,545 7,387 9,921 2,273 2,929 2,964
Book Value per Share
$15.73 $17.23 $9.07 $16.78 $7.81 $3.02 $1.51 ($0.30) ($1.91) ($2.80) ($3.48)
Tangible Book Value per Share
($45.76) ($104.13) ($90.68) ($71.59) ($64.07) ($63.17) ($59.00) ($54.30) ($49.85) ($51.10) ($48.71)
Total Capital
20,772 37,314 33,104 31,388 27,120 27,031 24,530 22,620 21,026 22,306 21,294
Total Debt
15,371 31,285 29,846 25,444 24,305 25,895 23,925 22,654 20,766 22,388 21,616
Total Long-Term Debt
15,228 30,265 29,845 25,235 24,077 24,661 23,925 22,654 20,334 21,938 18,942
Net Debt
15,048 30,688 29,304 24,647 23,582 22,651 22,109 20,535 20,202 21,426 20,415
Capital Expenditures (CapEx)
-1,200 222 235 171 157 270 302 269 218 215 337
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,243 617 927 -110 -120 -1,289 -1,387 -1,710 174 782 495
Debt-free Net Working Capital (DFNWC)
1,566 1,214 1,469 687 603 1,955 429 409 738 1,744 1,696
Net Working Capital (NWC)
1,423 194 1,468 478 375 721 429 409 306 1,294 -978
Net Nonoperating Expense (NNE)
791 1,357 2,012 -2,333 2,475 1,641 1,032 1,252 530 1,285 -595
Net Nonoperating Obligations (NNO)
15,048 30,685 27,025 24,647 23,582 22,651 22,109 20,535 20,202 21,426 20,415
Total Depreciation and Amortization (D&A)
1,684 2,612 2,984 3,009 2,898 2,138 1,886 1,607 1,493 1,352 1,404
Debt-free, Cash-free Net Working Capital to Revenue
15.15% 5.91% 9.58% -1.26% -1.43% -14.99% 0.00% -20.28% 2.14% 8.93% 5.14%
Debt-free Net Working Capital to Revenue
19.08% 11.62% 15.19% 7.87% 7.20% 22.73% 0.00% 4.85% 9.08% 19.92% 17.62%
Net Working Capital to Revenue
17.34% 1.86% 15.17% 5.48% 4.47% 8.38% 0.00% 4.85% 3.77% 14.78% -10.16%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$2.72 ($0.85) ($6.94) $6.86 ($11.81) ($5.08) ($1.58) ($2.64) ($0.62) ($1.62) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding
335.40M 342.70M 347.30M 350.20M 351.30M 352.10M 355.62M 358.90M 362M 364.90M 368M
Adjusted Diluted Earnings per Share
$2.67 ($0.85) ($6.94) $6.83 ($11.81) ($5.08) ($1.58) ($2.64) ($0.62) ($1.62) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding
341.50M 342.70M 347.30M 351.80M 351.30M 352.10M 355.62M 358.90M 362M 364.90M 368M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 ($5.08) ($1.58) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
336.20M 343.50M 347.84M 348.84M 350.99M 352.70M 355M 359.65M 362.04M 365.41M 367.93M
Normalized Net Operating Profit after Tax (NOPAT)
2,111 1,535 746 826 370 -68 553 842 949 1,100 1,125
Normalized NOPAT Margin
25.72% 14.69% 7.71% 9.47% 4.41% -0.79% 0.00% 9.98% 11.68% 12.57% 11.69%
Pre Tax Income Margin
12.84% -1.48% -25.17% -19.96% -49.57% -21.36% 0.00% -12.14% -1.59% -4.45% 1.74%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
1.69 0.90 -0.33 0.11 -1.31 -0.12 0.41 0.31 0.76 0.69 1.10
NOPAT to Interest Expense
1.52 0.68 -0.22 0.04 -0.93 -0.09 0.30 0.21 0.54 0.51 -0.49
EBIT Less CapEx to Interest Expense
2.78 0.76 -0.46 0.02 -1.40 -0.28 0.22 0.13 0.39 0.52 0.85
NOPAT Less CapEx to Interest Expense
2.61 0.54 -0.34 -0.05 -1.01 -0.25 0.11 0.03 0.17 0.35 -0.74
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.91% -3.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.91% -28.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Bausch Health Companies

This table displays calculated financial ratios and metrics derived from Bausch Health Companies' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-3.08% -0.14% 1.36% 10.17% 9.38% 9.80% 10.75% 10.89% 12.15% 6.27%
EBITDA Growth
-37.70% -83.09% -23.14% 27.76% -44.74% 471.20% 25.25% 1.67% 100.60% 23.11%
EBIT Growth
-56.50% -168.32% -40.65% 136.97% -97.21% 240.32% 61.21% -3.32% 4,442.86% 54.31%
NOPAT Growth
-55.87% -113.13% -38.60% 24.94% -95.62% 253.39% 60.57% -105.76% 2,171.43% 3.25%
Net Income Growth
110.99% -669.44% -216.67% 119.42% -194.79% 88.54% 63.16% -103.70% 75.92% 308.51%
EPS Growth
111.54% -638.10% -189.47% 117.50% -193.64% 90.27% 69.09% -57.14% 77.67% 318.18%
Operating Cash Flow Growth
-323.94% 1,879.17% 344.44% 67.48% 122.33% -17.89% 37.01% 84.47% 43.62% 54.10%
Free Cash Flow Firm Growth
-119.01% -103.64% -68.78% 506.37% 58.19% -398.10% -261.25% -144.38% 444.06% 340.64%
Invested Capital Growth
4.09% -0.19% -1.46% -5.48% 1.25% 4.31% 4.33% 2.84% -3.04% -5.86%
Revenue Q/Q Growth
4.02% 7.18% -11.35% 11.47% 3.28% 7.60% -10.59% 11.61% 4.45% 1.95%
EBITDA Q/Q Growth
8.19% -79.44% 296.00% 45.05% -53.20% 112.50% -13.17% 17.74% -7.67% 30.42%
EBIT Q/Q Growth
52.12% -198.80% 166.53% 136.97% -98.21% 4,871.43% -23.56% 42.11% -15.87% 68.87%
NOPAT Q/Q Growth
98.75% -173.75% 174.15% 14.95% -93.04% 2,485.71% -22.38% -104.12% 2,846.74% 17.54%
Net Income Q/Q Growth
389.93% -201.74% 49.02% 112.92% -1,514.81% 87.70% -63.83% 98.70% -9,100.00% 206.52%
EPS Q/Q Growth
375.00% -202.73% 51.33% 112.73% -1,571.43% 89.32% -54.55% 117.65% -866.67% 204.35%
Operating Cash Flow Q/Q Growth
-1,126.83% 137.61% -67.58% 33.77% 36.89% 38.30% -45.90% 80.09% 6.58% 48.40%
Free Cash Flow Firm Q/Q Growth
-88.06% 79.24% 434.79% 210.96% -119.35% -147.29% -8.38% 14.41% 249.99% 72.95%
Invested Capital Q/Q Growth
-1.20% -3.26% -0.95% -0.16% 5.83% -0.33% -0.93% -1.58% -0.23% -3.23%
Profitability Metrics
- - - - - - - - - -
Gross Margin
71.46% 70.27% 70.06% 70.05% 72.16% 70.72% 70.27% 70.08% 72.27% 71.59%
EBITDA Margin
29.72% 5.70% 25.46% 33.13% 15.01% 29.65% 28.80% 30.38% 26.85% 34.35%
Operating Margin
11.93% -10.76% 9.00% 19.01% 0.63% 15.03% 13.05% 16.19% 12.67% 21.81%
EBIT Margin
12.27% -11.31% 8.49% 18.04% 0.31% 14.45% 12.35% 15.73% 12.67% 20.98%
Profit (Net Income) Margin
19.70% -18.70% -10.75% 1.25% -17.07% -1.95% -3.58% -0.04% -3.67% 3.83%
Tax Burden Percent
91.80% 114.85% 153.68% 34.18% 117.18% 671.43% 111.59% -2.08% 438.10% 46.89%
Interest Burden Percent
174.90% 143.95% -82.42% 20.20% -4,657.14% -2.01% -25.94% 12.70% -6.60% 38.92%
Effective Tax Rate
8.20% 0.00% 0.00% 65.82% 0.00% 0.00% 0.00% 102.08% 0.00% 53.11%
Return on Invested Capital (ROIC)
0.00% -2.99% 2.52% 2.61% 0.18% 4.41% 3.96% -0.15% 3.98% 4.75%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -4.19% 0.89% 2.05% -1.67% 2.97% 2.64% -0.12% 2.51% 3.97%
Return on Net Nonoperating Assets (RNNOA)
0.00% -755.23% 9,100.85% 161.05% -358.15% 693.48% -3,765.62% -108.62% -224.36% -410.92%
Return on Equity (ROE)
181.21% -758.22% 9,103.37% 163.65% -357.98% 697.89% -3,761.67% -108.77% -220.38% -406.17%
Cash Return on Invested Capital (CROIC)
-0.44% 1.74% 2.65% -15.97% -0.04% -0.99% -0.63% 0.77% 7.57% 2.82%
Operating Return on Assets (OROA)
0.00% -3.35% 2.54% 5.61% 0.10% 4.77% 4.23% 5.57% 4.48% 7.50%
Return on Assets (ROA)
0.00% -5.53% -3.21% 0.39% -5.46% -0.64% -1.22% -0.01% -1.30% 1.37%
Return on Common Equity (ROCE)
-443.29% 2,677.25% -2,312,255.81% -423.50% 3,082.56% -6,720.13% -248,399.75% 4,543.69% -1,087.57% -2,313.37%
Return on Equity Simple (ROE_SIMPLE)
-51.43% 0.00% 44.38% 28.51% 82.54% 0.00% 42.96% 43.15% 18.48% 0.00%
Net Operating Profit after Tax (NOPAT)
224 -165 123 141 9.80 253 197 -8.10 223 262
NOPAT Margin
10.95% -7.53% 6.30% 6.50% 0.44% 10.52% 9.14% -0.34% 8.87% 10.22%
Net Nonoperating Expense Percent (NNEP)
-0.87% 1.20% 1.62% 0.55% 1.85% 1.44% 1.32% -0.03% 1.48% 0.78%
Return On Investment Capital (ROIC_SIMPLE)
- -0.79% - - - 1.14% - - - 1.23%
Cost of Revenue to Revenue
28.54% 29.73% 29.94% 29.95% 27.84% 29.28% 29.73% 29.92% 27.73% 28.41%
SG&A Expenses to Revenue
32.31% 30.37% 37.29% 32.81% 31.95% 31.81% 36.88% 34.62% 33.86% 32.04%
R&D to Revenue
6.50% 6.48% 7.36% 7.20% 6.84% 6.31% 7.01% 6.49% 5.82% 6.37%
Operating Expenses to Revenue
59.53% 81.03% 61.06% 51.04% 71.54% 55.69% 57.22% 53.89% 59.60% 49.79%
Earnings before Interest and Taxes (EBIT)
251 -248 165 391 7.00 348 266 378 318 537
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
608 125 495 718 336 714 620 730 674 879
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.28 0.36 0.35 0.35 0.33 0.43 0.28 0.32 0.31
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.14 1.14 1.18 1.18 1.19 1.19 1.24 1.18 1.19 1.21
Enterprise Value to Revenue (EV/Rev)
0.00 2.88 2.94 2.85 3.00 2.89 2.91 2.67 2.61 2.53
Enterprise Value to EBITDA (EV/EBITDA)
9.47 12.08 13.41 12.23 15.29 11.18 10.94 10.23 9.02 8.38
Enterprise Value to EBIT (EV/EBIT)
22.87 52.53 72.07 42.59 81.24 27.77 25.82 24.57 18.84 16.24
Enterprise Value to NOPAT (EV/NOPAT)
32.66 73.71 99.67 0.00 100.16 37.52 34.93 33.52 26.12 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 22.91 24.51 24.00 19.43 17.81 15.24
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 65.66 44.38 0.00 0.00 0.00 0.00 156.12 15.46 41.64
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
49.00 79.87 142.43 75.84 -95.45 -273.02 -126.86 -95.42 -88.87 -67.13
Long-Term Debt to Equity
48.05 78.21 139.36 74.20 -93.17 -267.54 -123.77 -93.43 -87.00 -58.83
Financial Leverage
138.16 180.25 10,207.50 78.47 213.98 233.87 -1,429.00 931.84 -89.42 -103.57
Leverage Ratio
186.41 242.87 13,633.75 102.43 269.51 297.96 -1,805.45 1,181.77 -112.38 -133.35
Compound Leverage Factor
326.03 349.61 -11,237.52 20.70 -12,551.24 -5.99 468.33 150.07 7.42 -51.90
Debt to Total Capital
98.00% 98.76% 99.30% 98.70% 101.06% 100.37% 100.79% 101.06% 101.14% 101.51%
Short-Term Debt to Total Capital
1.90% 2.05% 2.14% 2.13% 2.42% 2.02% 2.46% 2.11% 2.13% 12.56%
Long-Term Debt to Total Capital
96.10% 96.71% 97.16% 96.57% 98.64% 98.35% 98.34% 98.95% 99.01% 88.95%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
4.43% 4.53% 4.54% 4.49% 4.26% 4.21% 4.30% 4.42% 4.38% 4.49%
Common Equity to Total Capital
-2.43% -3.29% -3.85% -3.18% -5.32% -4.58% -5.09% -5.48% -5.52% -6.01%
Debt to EBITDA
8.31 10.71 11.54 10.56 13.40 9.89 9.24 9.03 7.86 7.45
Net Debt to EBITDA
8.12 10.42 11.24 10.26 12.93 9.47 8.93 8.77 7.58 7.03
Long-Term Debt to EBITDA
8.15 10.49 11.29 10.33 13.08 9.69 9.02 8.84 7.69 6.53
Debt to NOPAT
28.67 65.34 85.77 -4.57 87.79 33.21 29.50 29.58 22.76 -32.43
Net Debt to NOPAT
28.00 63.57 83.56 -4.44 84.74 31.78 28.49 28.73 21.97 -30.63
Long-Term Debt to NOPAT
28.12 63.98 83.92 -4.47 85.69 32.54 28.78 28.96 22.28 -28.42
Altman Z-Score
-0.38 -0.15 -0.09 -0.04 -0.09 -0.02 -0.02 -0.03 -0.02 -0.07
Noncontrolling Interest Sharing Ratio
344.63% 453.10% 25,500.00% 358.78% 961.11% 1,062.92% -6,503.45% 4,277.27% -393.50% -469.55%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.05 1.08 1.08 1.12 1.20 1.30 1.23 1.19 1.19 0.86
Quick Ratio
0.58 0.60 0.56 0.59 0.64 0.68 0.63 0.62 0.62 0.49
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-608 -126 423 1,314 -254 -629 -681 -583 875 1,513
Operating Cash Flow to CapEx
-2,338.89% 719.70% 327.66% 735.71% 671.43% 397.96% 257.32% 487.18% 570.42% 566.98%
Free Cash Flow to Firm to Interest Expense
0.00 -1.10 1.38 4.12 -0.75 -1.74 -1.98 -1.73 2.53 4.49
Operating Cash Flow to Interest Expense
0.00 4.13 0.50 0.65 0.83 1.08 0.61 1.12 1.17 1.78
Operating Cash Flow Less CapEx to Interest Expense
0.00 3.56 0.35 0.56 0.71 0.81 0.38 0.89 0.97 1.47
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.30 0.30 0.31 0.32 0.33 0.34 0.35 0.35 0.36
Accounts Receivable Turnover
0.00 4.56 5.01 4.93 4.63 4.62 4.80 4.79 4.69 4.65
Inventory Turnover
0.00 2.27 2.11 2.13 2.15 1.94 1.83 1.88 1.89 1.77
Fixed Asset Turnover
0.00 5.08 5.13 5.31 5.53 5.30 5.42 5.52 5.62 5.52
Accounts Payable Turnover
0.00 5.09 4.64 4.69 4.75 4.13 4.35 4.91 4.47 4.05
Days Sales Outstanding (DSO)
0.00 80.09 72.87 74.05 78.77 78.94 76.05 76.26 77.86 78.46
Days Inventory Outstanding (DIO)
0.00 160.81 172.75 171.11 169.54 187.85 199.31 193.71 193.54 205.92
Days Payable Outstanding (DPO)
0.00 71.64 78.64 77.75 76.83 88.43 83.89 74.30 81.73 90.20
Cash Conversion Cycle (CCC)
0.00 169.25 166.97 167.41 171.48 178.36 191.46 195.66 189.68 194.18
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
21,151 20,462 20,267 20,235 21,415 21,344 21,145 20,810 20,763 20,093
Invested Capital Turnover
0.00 0.40 0.40 0.40 0.40 0.42 0.43 0.45 0.45 0.46
Increase / (Decrease) in Invested Capital
832 -39 -300 -1,173 264 882 878 575 -652 -1,251
Enterprise Value (EV)
24,168 23,427 24,000 23,808 25,590 25,295 26,135 24,542 24,685 24,336
Market Capitalization
2,492 2,273 2,933 2,910 2,995 2,929 3,875 2,557 2,996 2,964
Book Value per Share
($1.45) ($1.91) ($2.21) ($1.82) ($3.24) ($2.80) ($3.04) ($3.20) ($3.20) ($3.48)
Tangible Book Value per Share
($51.29) ($49.85) ($49.53) ($48.36) ($52.41) ($51.10) ($50.32) ($49.63) ($49.02) ($48.71)
Total Capital
21,648 21,026 20,798 20,823 22,195 22,306 21,900 21,433 21,265 21,294
Total Debt
21,215 20,766 20,653 20,552 22,430 22,388 22,074 21,660 21,507 21,616
Total Long-Term Debt
20,804 20,334 20,207 20,108 21,894 21,938 21,536 21,208 21,054 18,942
Net Debt
20,718 20,202 20,122 19,964 21,650 21,426 21,319 21,037 20,757 20,415
Capital Expenditures (CapEx)
54 66 47 28 42 98 82 78 71 106
Debt-free, Cash-free Net Working Capital (DFCFNWC)
93 174 229 350 580 782 774 671 548 495
Debt-free Net Working Capital (DFNWC)
590 738 760 938 1,360 1,744 1,529 1,294 1,298 1,696
Net Working Capital (NWC)
179 306 314 494 824 1,294 991 842 845 -978
Net Nonoperating Expense (NNE)
-179 245 332 114 392 300 274 -7.10 315 164
Net Nonoperating Obligations (NNO)
20,718 20,202 20,122 19,964 21,650 21,426 21,319 21,037 21,005 20,415
Total Depreciation and Amortization (D&A)
357 373 330 327 329 366 354 352 356 342
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 2.14% 2.81% 4.19% 6.79% 8.93% 8.63% 7.29% 5.78% 5.14%
Debt-free Net Working Capital to Revenue
0.00% 9.08% 9.33% 11.23% 15.92% 19.92% 17.05% 14.06% 13.70% 17.62%
Net Working Capital to Revenue
0.00% 3.77% 3.85% 5.92% 9.65% 14.78% 11.05% 9.15% 8.92% -10.16%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$1.10 ($1.13) ($0.55) $0.07 ($1.03) ($0.11) ($0.17) $0.03 ($0.23) $0.24
Adjusted Weighted Average Basic Shares Outstanding
362.50M 362M 363.30M 364.80M 365.40M 364.90M 366.80M 367.90M 368.40M 368M
Adjusted Diluted Earnings per Share
$1.10 ($1.13) ($0.55) $0.07 ($1.03) ($0.11) ($0.17) $0.03 ($0.23) $0.24
Adjusted Weighted Average Diluted Shares Outstanding
363.40M 362M 363.30M 367.10M 365.40M 364.90M 366.80M 370.20M 368.40M 368M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
361.87M 362.04M 363.72M 364.33M 365.20M 365.41M 366.80M 367.10M 367.80M 367.93M
Normalized Net Operating Profit after Tax (NOPAT)
343 274 139 326 304 333 206 284 223 412
Normalized NOPAT Margin
16.78% 12.48% 7.13% 15.02% 13.57% 13.81% 9.56% 11.83% 8.90% 16.08%
Pre Tax Income Margin
21.46% -16.28% -7.00% 3.65% -14.57% -0.29% -3.20% 2.00% -0.84% 8.17%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 -2.16 0.54 1.23 0.02 0.96 0.77 1.12 0.92 1.59
NOPAT to Interest Expense
0.00 -1.44 0.40 0.44 0.03 0.70 0.57 -0.02 0.64 0.78
EBIT Less CapEx to Interest Expense
0.00 -2.73 0.38 1.14 -0.10 0.69 0.53 0.89 0.71 1.28
NOPAT Less CapEx to Interest Expense
0.00 -2.01 0.25 0.35 -0.10 0.43 0.33 -0.25 0.44 0.46
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Bausch Health Companies' Financials

When does Bausch Health Companies's financial year end?

According to the most recent income statement we have on file, Bausch Health Companies' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bausch Health Companies' net income changed over the last 10 years?

Bausch Health Companies' net income appears to be on an upward trend, with a most recent value of -$72 million in 2024, falling from $880 million in 2014. The previous period was -$611 million in 2023.

What is Bausch Health Companies's operating income?
Bausch Health Companies's total operating income in 2024 was $1.55 billion, based on the following breakdown:
  • Total Gross Profit: $6.84 billion
  • Total Operating Expenses: $5.30 billion
How has Bausch Health Companies revenue changed over the last 10 years?

Over the last 10 years, Bausch Health Companies' total revenue changed from $8.21 billion in 2014 to $9.63 billion in 2024, a change of 17.3%.

How much debt does Bausch Health Companies have?

Bausch Health Companies' total liabilities were at $26.85 billion at the end of 2024, a 2.1% decrease from 2023, and a 28.4% increase since 2014.

How much cash does Bausch Health Companies have?

In the past 10 years, Bausch Health Companies' cash and equivalents has ranged from $322.60 million in 2014 to $3.24 billion in 2019, and is currently $1.18 billion as of their latest financial filing in 2024.

How has Bausch Health Companies' book value per share changed over the last 10 years?

Over the last 10 years, Bausch Health Companies' book value per share changed from 15.73 in 2014 to -3.48 in 2024, a change of -122.1%.



This page (NYSE:BHC) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners